CLDX Celldex Therapeutics, Inc.companySEC Filings & Insider Trading Activity 2026
Latest Celldex Therapeutics, Inc. (CLDX) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on February 25, 2026, a 10-Q quarterly report filed on November 10, 2025, an 8-K current report filed on April 2, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Celldex Therapeutics, Inc. (CLDX) (SEC CIK 744218), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 10-K Annual Report AnalysisLatest 10-K (2025-12-31)
Business Overview
- • Core business model: Development of therapeutic antibodies targeting mast cell biology for severe inflammatory and autoimmune diseases
- • New emphasis on bispecific antibody platform, highlighted by CDX-622 targeting TSLP and SCF with Phase 1 studies initiated in 2024-2026
Risk Factors
- • FDA regulatory delays from recent 43-day government shutdown Oct-Nov 2025 impacting review timelines
- • Global supply chain disruptions threatening clinical trial material supplies and contract manufacturing capacity
Management Discussion & Analysis
- • No revenue or YoY change disclosed; focus on clinical R&D for barzolvolimab and CDX-622
- • R&D expenses $245.1M in 2025 vs $163.6M in 2024 and $118.0M in 2023, driven by barzolvolimab program ($198.3M in 2025)
AI 10-Q Quarterly Report AnalysisLatest 10-Q (2025-09-30)
Risk Factors
- • No material changes to risk factors from 10-K dated February 27, 2025
- • New Employment Agreement for CCO Teri Lawver with $550K salary, 45% bonus target, severance up to 24 months’ pay post Change in Control
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 2.02: Results of Operations and Financial Condition
- • Q4 and full-year 2025 financial results announced Feb 25, 2026
- • Full results in Exhibit 99.1 — key figures, pipeline updates, and guidance (if any) found there
Annual Reports Archive10-K
AI-powered analysis of Celldex Therapeutics, Inc. (CLDX) 10-K annual reports filed with SEC EDGAR.
Quarterly Reports Archive10-Q
AI-powered analysis of Celldex Therapeutics, Inc. (CLDX) 10-Q quarterly reports filed with SEC EDGAR.
Recent 8-K FilingsCurrent Reports
AI-powered analysis of Celldex Therapeutics, Inc. (CLDX) 8-K current reports disclosing material events.
Financial SummaryXBRL
| FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Revenue | $2.4M | $6.9M | $7.0M | $1.5M |
| Operating Income | -$115.2M | -$154.5M | -$195.1M | -$287.4M |
| Net Income | -$112.3M | -$141.4M | -$157.9M | -$258.8M |
| Op. Margin | -4889.0% | -2245.3% | -2778.9% | -18599.8% |
| Net Margin | -4765.6% | -2054.8% | -2248.8% | -16748.0% |
| Balance Sheet | ||||
| Total Assets | $352.7M | $465.6M | $792.3M | $583.0M |
| Equity | $326.2M | $429.2M | $747.0M | $527.2M |
| ROE | -34.4% | -33.0% | -21.1% | -49.1% |
Source: XBRL financial data from Celldex Therapeutics, Inc. (CLDX) 10-K filings on SEC EDGAR. All figures in USD. Key metrics include revenue, net income, gross profit, gross profit margin, operating income, EPS (diluted), total assets, stockholders' equity, return on equity (ROE), operating cash flow, and capital expenditure.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Apr 2, 2026 | — | — | — |
8-K | Feb 25, 2026 | — | Analysis | — |
10-K | Feb 25, 2026 | Dec 31, 2025 | Analysis | |
10-Q | Nov 10, 2025 | Sep 30, 2025 | Analysis | |
10-Q | Aug 7, 2025 | Jun 30, 2025 | — | |
10-Q | May 8, 2025 | Mar 31, 2025 | — | |
10-K | Feb 27, 2025 | Dec 31, 2024 | — | |
10-Q | Nov 6, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 8, 2024 | Jun 30, 2024 | — | |
10-Q | May 6, 2024 | Mar 31, 2024 | — | |
10-K | Feb 26, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 2, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 8, 2023 | Jun 30, 2023 | — | |
10-Q | May 4, 2023 | Mar 31, 2023 | — | |
10-K | Feb 28, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 9, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 8, 2022 | Jun 30, 2022 | — | |
10-Q | May 5, 2022 | Mar 31, 2022 | — | |
10-K | Feb 28, 2022 | Dec 31, 2021 | — | |
10-Q | Nov 9, 2021 | Sep 30, 2021 | — | |
10-Q | Aug 5, 2021 | Jun 30, 2021 | — | |
10-Q | May 6, 2021 | Mar 31, 2021 | — | |
10-K | Mar 29, 2021 | Dec 31, 2020 | — | |
10-Q | Nov 5, 2020 | Sep 30, 2020 | — | |
10-Q | Aug 6, 2020 | Jun 30, 2020 | — |
Frequently Asked Questions
What are the latest CLDX SEC filings in 2026?
Celldex Therapeutics, Inc. (CLDX) has filed a 10-K annual report on February 25, 2026, a 10-Q quarterly report on November 10, 2025, an 8-K current report on April 2, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did CLDX file its most recent 10-K annual report?
Celldex Therapeutics, Inc. (CLDX) filed its most recent 10-K annual report on February 25, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view CLDX 10-Q quarterly reports?
Celldex Therapeutics, Inc. (CLDX)'s most recent 10-Q quarterly report was filed on November 10, 2025. SignalX displays every CLDX 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has CLDX filed recently?
Celldex Therapeutics, Inc. (CLDX)'s most recent 8-K was filed on April 2, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find CLDX insider trading activity (Form 4)?
SignalX aggregates every CLDX Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does CLDX file with the SEC?
Celldex Therapeutics, Inc. (CLDX) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new CLDX filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Celldex Therapeutics, Inc. (CLDX).
What is CLDX's SEC CIK number?
Celldex Therapeutics, Inc. (CLDX)'s SEC CIK (Central Index Key) number is 744218. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 744218 to look up all CLDX filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find CLDX return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from Celldex Therapeutics, Inc. (CLDX) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of Celldex Therapeutics, Inc. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 79+ filings.